Lymphomas

FDA Grants Fast Track Designation to Novel Small Molecule Drug in LPL and WM

May 26, 2020

"Fast Track Designation for lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinemia further supports our clinical development strategy to quickly and efficiently provide these patients with an effective therapeutic alternative."

Addition of Alemtuzumab Improves Responses in Elderly Patients With Peripheral T-Cell Lymphomas

May 19, 2020

“This randomized phase III study for the first time provides prospective long-term results on survival and other end points of interest after standard treatment with CHOP in patients with PTCL beyond 60 years who represent the majority of [patients with] PTCL, generally less eligible for more intense therapies like autologous and allogeneic transplantation."

Trametinib Misses the Mark in BRAF Non-V600-Mutant Solid Tumors and Lymphomas

April 29, 2020

"Single-agent trametinib had low rates of clinical activity in patients with heavily pretreated, metastatic cancers harboring non-V600 mutations in BRAF. This contrasts with a number of case reports, largely in melanoma, showing responses in patients with these mutations."

ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin Lymphoma

April 29, 2020

Tatyana Feldman, MD, discusses the design and efficacy of the ECHELON-1 trial investigating brentuximab vedotin with chemotherapy in patients with stage III or IV Hodgkin lymphoma after a 3-year update.

Community Oncologists Critical to Success of CAR T-cell Therapy in R/R Large B-Cell Lymphoma

April 28, 2020

Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.

FDA Grants RMAT Designation to Tisagenlecleucel in R/R Follicular Lymphoma

April 22, 2020

“This designation supports the advancement of Kymriah, which could potentially address an unmet need in certain patients with follicular lymphoma, as we strive to reimagine medicine at Novartis. These patients are often faced with the burden of several years of various treatments as their disease continues to progress.”

Indolent Non-Hodgkin Lymphomas Still Require More Durable Treatment Options

April 20, 2020

In an interview with Targeted Oncology, Sonali M. Smith, MD, discussed the treatment landscape for patients with indolent non-Hodgkin lymphoma. In particular, she highlighted the data supporting the use of rituximab plus lenalidomide in patients with follicular lymphoma and marginal zone lymphoma.

CAR T-Cell Therapy Appears Promising in Relapsed/Refractory DLBCL

April 15, 2020

David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.

Options for Treating Relapsed/Refractory Follicular Lymphoma

April 03, 2020

Sonali M. Smith, MD, discusses how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.

FDA Grants Fast Track Designation for ME-401 in Relapsed/Refractory FL

April 01, 2020

The FDA has granted Fast Track Therapy designation to ME-401, an investigational selective oral inhibitor of phosphatidylinositol 3-kinase inhibitor as treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.